Publication of the successful Phase 1 FDA trial evaluating Poly-Zinc-Liothyronine (PZL), a novel extended release T3 product discovered and developed by Synthonics to help manage difficult to treat hypothyroidism and other medical disorders, in Thyroid. If eventually approved by the FDA, PZL would significantly improve the quality of life of millions of individuals that suffer from hypothyroidism, potentially help patients with refractory depression, fatigue and heart failure, and would be the first novel thyroid medication to be approved in last 30 years.
Read more about it here